Obesity is one of the most common physical health care problems among persons with severe and persistent mental illness. Obesity is a complex multifactorial chronic disease that develops from the interaction between genotype and the environment. Among individuals with serious mental illnesses, an unhealthy lifestyle, as well as the effects of psychotropic medications, such as second generation antipsychotics, can contribute to the development of this problem. Excess body weight increases the risk for many medical problems, including type 2 diabetes mellitus, coronary heart disease, osteoarthritis, hypertension, and gallbladder disease. Monitoring body weight is essential, and weight gain early in treatment can help predict those at high risk for substantial weight gain. Children, adolescents, and first-episode patients are at higher risk for weight gain. Lifestyle therapies and other non-pharmacological interventions have been shown to be effective in controlled clinical trials, but the evidence base for adjunctive medication strategies such as with orlistat, sibutramine, amantadine, nizatidine, metformin, topiramate, and others, is conflicting. Switching antipsychotic medication may or may not be clinically feasible, but can lead to a reduction in body weight. At the very least, a ‘small steps approach’ to managing weight should be offered to all patients who are started on second generation antipsychotics.